--- a
+++ b/clusters/9knumclustersv2/clust_1427.txt
@@ -0,0 +1,50 @@
+One or more metastatic tumors measurable per RECIST Criteria
+Measurable disease as per RECIST v. criteria
+Must have measurable disease per RECIST v. Response Criteria
+INCLUSION CRITERIA FOR REGISTRATION (HER MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of measurable or non-measurable disease by RECIST . is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST . is required
+Measurable disease by RECIST . criteria
+Have measurable or non-measurable disease per RECIST . criteria for solid tumors and RANO criteria for HGG
+Measurable disease by RECIST . criteria
+Measurable disease as per RECIST v. criteria
+Have measurable disease per RECIST . criteria present
+Measurable disease by per RECIST . criteria; radiographic tumor assessment performed within  days of registration.
+All patients enrolled will be required to have measurable disease by RECIST . criteria
+New or increasing non-bone disease (RECIST . criteria);
+Measurable disease by RECIST . criteria
+Patients must have measurable disease by RECIST criteria
+Have measurable disease per RECIST . criteria present
+Have measurable disease per RECIST . or irRECIST criteria present
+Measurable disease as per the RECIST criteria v .
+Measurable disease according to PET Response Criteria, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
+CERITINIB INCLUSION CRITERIA: Measurable disease by RECIST v.
+REGORAFENIB INCLUSION CRITERIA: Measurable disease by RECIST v.
+ENTRECTINIB INCLUSION CRITERIA: Measurable disease by RECIST v.
+Patients must have measurable disease by the Modified RECIST criteria
+Measurable disease as per RECIST . criteria.
+Patients must have measurable disease per RECIST . criteria; all sites of disease must be evaluated within  weeks prior to randomization
+Measurable disease per RECIST . criteria
+Have measurable disease per RECIST . criteria
+Measurable disease by RECIST . criteria
+Progressive measurable disease: using conventional solid tumour criteria RECIST ..
+Disease must be measurable by RECIST . criteria
+Subjects must have measurable disease by CT or MRI per RECIST . criteria (radiographic tumor assessment performed within  days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST .
+Measurable disease per RECIST . criteria
+Participants must have measurable disease by RECIST . criteria
+Measurable disease as assessed by RECIST . criteria (Appendix A).
+Measurable disease as assessed by modified RECIST for MPM and by RECIST . criteria for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid carcinoma
+Measurable disease by RECIST . criteria
+Measurable disease by RECIST . criteria
+Participants in the Phase II portion of the trial must have measurable disease by RECIST . criteria
+Breast cancer participants must have measurable disease by RECIST criteria
+For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:
+Measurable disease by RECIST . criteria.
+Measurable disease at screening by RECIST . criteria
+Measurable disease by RECIST v. criteria
+Measurable disease as assessed by RECIST . criteria (Appendix A).
+Measurable disease by RECIST . criteria
+Measurable disease as assessed by RECIST . criteria (Appendix A).
+Measurable disease on baseline imaging per RECIST . criteria
+Patients must have measurable disease by RECIST . criteria
+Measurable disease per RECIST . criteria
+Measurable disease by RECIST criteria
+Measurable disease as per RECIST v. criteria